Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Alison Sexton Ward, PhD
Advertisement
Articles by Alison Sexton Ward, PhD
Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.
Advertisement
Latest Updated Articles
- Estimating the Social Value of G-CSF Therapies in the United States
Published: October 10th 2016 | Updated:
- The Long-term Social Value of Granulocyte Colony-Stimulating Factors
Published: October 4th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Rural-Urban Disparities in Colorectal Cancer Screening Persist
2
Medicaid Work Rules Could Strain Hospitals: Laxmi Patel
3
Insurance Coverage Improves for Same-Sex Couples, Yet Disparities Persist
4
Identifying Barriers to Colorectal Cancer Screening for People With IDD
5
